{"filing":{"accession_number":"0001104659-26-111142","cik":"0001574232","ticker":"ADXN","company_name":"Addex Therapeutics Ltd.","form":"6-K","filing_date":"2026-09-28","report_date":"2026-06-30","primary_document":"adxn-20260630x6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1574232/000110465926111142/adxn-20260630x6k.htm"},"events":[{"id":35286,"run_id":32497,"accession_number":"0001104659-26-111142","anchor_item_number":"EX-99.3","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a press release disclosing Addex Therapeutics' 2026 half-year financial results, including consolidated financial statements, key operating metrics (R\u0026D and G\u0026A expenses, net loss, cash position), and a corporate update. The document explicitly states \"Addex Therapeutics Reports 2026 Half-Year Results\" and provides detailed financial tables comparing H1 2026 to H1 2025, along with operational highlights including a USD 2.8 million capital raise and regaining of GABAB PAM rights from Indivior. This is a periodic interim financial results announcement, material to investors assessing the company's financial condition and progress.","company_name":"Addex Therapeutics Ltd.","ticker":"ADXN","filing_date":"2026-09-28","form":"6-K","submitted_at":null,"items":[{"id":39290,"accession_number":"0001104659-26-111142","item_number":"EX-99.3","item_title":"adxn-ex99d3.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a press release disclosing Addex Therapeutics' 2026 half-year financial results, including consolidated financial statements, key operating metrics (R\u0026D and G\u0026A expenses, net loss, cash position), and a corporate update. The document explicitly states \"Addex Therapeutics Reports 2026 Half-Year Results\" and provides detailed financial tables comparing H1 2026 to H1 2025, along with operational highlights including a USD 2.8 million capital raise and regaining of GABAB PAM rights from Indivior. This is a periodic interim financial results announcement, material to investors assessing the company's financial condition and progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-28T11:15:50.232755+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":39288,"accession_number":"0001104659-26-111142","item_number":"EX-99.1","item_title":"adxn-20260630xex99d1.htm","event_type":"periodic_quarterly","event_domain":"periodic","is_material":false,"confidence":0.95,"reasoning":"This exhibit is the unaudited interim condensed consolidated financial statements for Addex Therapeutics Ltd. for the six-month period ended June 30, 2026. The document is clearly labeled as \"Unaudited Interim Condensed Consolidated Financial Statements\" and contains XBRL-tagged financial data covering Q2 2026 (six months ended 2026-06-30). This is a periodic interim financial report, not a discrete event or earnings release announcement.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-28T11:15:50.232755+00:00","company_name":"Addex Therapeutics Ltd.","ticker":"ADXN","filing_date":"2026-09-28"},{"id":39289,"accession_number":"0001104659-26-111142","item_number":"EX-99.2","item_title":"adxn-ex99d2.htm","event_type":"periodic_interim","event_domain":"periodic","is_material":false,"confidence":0.95,"reasoning":"This exhibit is Management's Discussion and Analysis (MD\u0026A) of Financial Condition and Results of Operations for the six-month period ended June 30, 2026. It is a periodic interim financial report (the foreign-issuer equivalent of a 10-Q), not a discrete event or earnings release. The document presents consolidated financial statements, revenue recognition policies, operating expense breakdowns, and comparative analysis of results for interim periods—all hallmarks of a periodic financial filing deferred for separate processing rather than an event-driven disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-28T11:15:50.232755+00:00","company_name":"Addex Therapeutics Ltd.","ticker":"ADXN","filing_date":"2026-09-28"},{"id":39290,"accession_number":"0001104659-26-111142","item_number":"EX-99.3","item_title":"adxn-ex99d3.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a press release disclosing Addex Therapeutics' 2026 half-year financial results, including consolidated financial statements, key operating metrics (R\u0026D and G\u0026A expenses, net loss, cash position), and a corporate update. The document explicitly states \"Addex Therapeutics Reports 2026 Half-Year Results\" and provides detailed financial tables comparing H1 2026 to H1 2025, along with operational highlights including a USD 2.8 million capital raise and regaining of GABAB PAM rights from Indivior. This is a periodic interim financial results announcement, material to investors assessing the company's financial condition and progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-28T11:15:50.232755+00:00","company_name":"Addex Therapeutics Ltd.","ticker":"ADXN","filing_date":"2026-09-28"}]}